In today’s recent session, 0.74 million shares of the Novavax, Inc. (NASDAQ:NVAX) have been traded, and its beta is 2.05. Most recently the company’s share price was $10.44, and it changed around $0.19 or 1.85% from the last close, which brings the market valuation of the company to $1.67B. NVAX at last check was trading at a discount to its 52-week high of $23.86, offering almost -128.54% off that amount. The share price’s 52-week low was $3.53, which indicates that the recent value has risen by an impressive 66.19% since then. We note from Novavax, Inc.’s average daily trading volume that its 10-day average is 7.8 million shares, with the 3-month average coming to 6.55 million.
Novavax, Inc. stock received a consensus recommendation rating of Hold, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 5 recommended NVAX as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Novavax, Inc. is expected to report earnings per share of -0.83 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novavax, Inc. (NASDAQ:NVAX) trade information
Instantly NVAX has been showing a green trend so far today with a performance of 1.85% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.48 on recent trading dayincreased the stock’s daily price by 0.38%. The company’s shares are currently up 117.50% year-to-date, but still up 3.16% over the last five days. On the other hand, Novavax, Inc. (NASDAQ:NVAX) is -17.34% down in the 30-day period. We can see from the shorts that 35.72 million shares have been sold at a short interest cover period of 5.59 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 52.55% from its current value. Analyst projections state that NVAX is forecast to be at a low of $14 and a high of $174.
Novavax, Inc. (NVAX) estimates and forecasts
Novavax, Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 141.11 percent over the past six months and at a 83.36% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 34.10% in revenue this quarter, and will report an increase of 87.50% in the next quarter. The year-over-year growth rate is expected to be -22.60%, down from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 65.77M in revenue for the current quarter. 4 analysts expect Novavax, Inc. to make 192.07M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 186.99M and 291.34M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -64.80%. Forecasts for the next quarter put sales growth at -34.10%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.55%. Novavax, Inc. earnings are expected to increase by 81.38% in 2024, but the outlook is positive 37.90% per year for the next five years.
NVAX Dividends
Novavax, Inc.’s next quarterly earnings report is expected to be released on 2024-Nov-07.
Novavax, Inc. (NASDAQ:NVAX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.38% of Novavax, Inc. shares, and 54.19% of them are in the hands of institutional investors. The stock currently has a share float of 56.67%. Novavax, Inc. stock is held by 306.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 10.0599% of the shares, which is about 14.08 million shares worth $178.19 million.
BLACKROCK INC., with 8.4669% or 11.85 million shares worth $149.98 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Jun 30, 2024. The former held 4.25 shares worth $43.99 million, making up 2.66% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 4.23 shares worth around $43.72 million, which represents about 2.64% of the total shares outstanding.
